1.20

0.84% 0.01

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $1.20, with a volume of 439.34K. It is up +0.84% in the last 24 hours and up +6.19% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$1.19

Open:

$1.2

24h Volume:

439.34K

Relative Volume:

0.54

Market Cap:

$37.05M

Revenue:

$680.00K

Net Income/Loss:

$-75.33M

P/E Ratio:

-0.1939

EPS:

-6.1898

Net Cash Flow:

$-57.38M

1W Performance:

+8.11%

1M Performance:

+6.19%

6M Performance:

-34.43%

1Y Performance:

-30.64%

1-Day Range:

$1.175

$1.23

1-Week Range:

$1.10

$1.27

52-Week Range:

$1.01

$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2026-08-11

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	1.20	37.05M	680.00K	-75.33M	-57.38M	-6.1898
TAK Takeda Pharmaceutical Co Adr	15.63	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.96	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.48	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	78.71	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	536.59	22.78B	3.17B	1.29B	1.01B	27.09

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Jun 17, 2026

BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan

Jun 17, 2026

BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan

Jun 17, 2026

BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan

Jun 17, 2026

BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan

Jun 17, 2026